“Future value targeting” was the buzzword from Sunday morning’s NACDS Annual Business Program. NACDS’ “Future Value Targeting” initiative will continually look forward and anticipate the underlying issues that will impact the industry.
Legislation pending in both houses of Congress regarding DIR, or direct and indirect remuneration, fees are giving hope to drug stores and two of the industry’s largest advocacy groups that pharmacy benefits management companies will stop retroactively reducing payments.
Although 2016 saw the Food and Drug Administration approve only 22 new drugs compared with 45 approvals in 2015 and the lowest tally since 2010, many in the pharmaceutical arena remain optimistic that this year will see a reversal of that trend.
State senators voted 22-9 in favor of approving a measure intended to help ease the state’s growing opioid epidemic.
The Canadian Pharmacists Association on Thursday expressed its concern over pharmacists being left out of recently introduced legislation tweaking the country’s marijuana laws to legalize recreational pot while preserving a separate stream for medical marijuana.
Retired Four-Star Marine Gen. John Allen, speak at the Business Program on Sunday, April 23, while Richard W. Fisher, who served as president and CEO of the Federal Reserve Bank of Dallas from 2005 to 2015, will speak at the Business Program on Tuesday, April 25.
The National Community Pharmacists Association is backing legislation that it says would improve pharmacy access for seniors with Medicare Part D drug plans.
The Food and Drug Administration has authorized 23andMe to market its Personal Genome Service Genetic Health Risk tests for 10 diseases or conditions directly to consumers.
Thomas Moriarty, who joined the company in 2012, will bring together corporate communications, legal, government affairs and public policy under one operating unit to manage the company's external affairs in Washington, D.C. and state capitals across the country.